Ashton Thomas Securities LLC Makes New Investment in Eli Lilly and Company $LLY

Key Points

• Ashton Thomas Securities LLC acquired 3,359 Eli Lilly shares worth approximately $3.09 million in the first quarter. Institutional investors and hedge funds collectively own 82.53% of the company.
• Eli Lilly reported a strong quarter, with EPS of $8.55 and revenue of $19.80 billion, exceeding estimates by $1.58 per share and $1.98 billion, respectively; revenue rose 55.5% year over year.
• Analysts maintain a favorable outlook, with a consensus “Moderate Buy” rating and an average price target of $1,283.64 versus the reported share price of $1,210.32. The company also declared a quarterly dividend of $1.73 per share, yielding 0.6% annually.

Ashton Thomas Securities LLC bought a new stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 3,359 shares of the company's stock, valued at approximately $3,090,000.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Maryland Capital Advisors Inc. acquired a new stake in Eli Lilly and Company in the fourth quarter worth $25,000. Osbon Capital Management LLC acquired a new position in shares of Eli Lilly and Company during the fourth quarter valued at $25,000. Basso Capital Management L.P. bought a new position in shares of Eli Lilly and Company during the fourth quarter worth about $30,000. Maseco LLP grew its position in shares of Eli Lilly and Company by 466.7% during the first quarter. Maseco LLP now owns 34 shares of the company's stock worth $31,000 after acquiring an additional 28 shares during the last quarter. Finally, E Fund Management Hong Kong Co. Ltd. increased its holdings in shares of Eli Lilly and Company by 342.9% in the 4th quarter. E Fund Management Hong Kong Co. Ltd. now owns 31 shares of the company's stock worth $32,000 after acquiring an additional 24 shares during the period. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company Price Performance

NYSE LLY opened at $1,210.32 on Thursday. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $1,249.45. The company has a debt-to-equity ratio of 1.26, a current ratio of 1.50 and a quick ratio of 1.10. The firm has a market capitalization of $1.14 trillion, a PE ratio of 43.00, a P/E/G ratio of 1.52 and a beta of 0.51. The company's 50 day simple moving average is $1,148.72 and its 200 day simple moving average is $1,042.77.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings data on Thursday, April 30th. The company reported $8.55 EPS for the quarter, topping analysts' consensus estimates of $6.97 by $1.58. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The company had revenue of $19.80 billion for the quarter, compared to the consensus estimate of $17.82 billion. During the same quarter in the previous year, the business earned $3.34 EPS. The company's quarterly revenue was up 55.5% compared to the same quarter last year. As a group, equities research analysts forecast that Eli Lilly and Company will post 34.91 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, September 10th. Investors of record on Friday, August 14th will be paid a dividend of $1.73 per share. The ex-dividend date of this dividend is Friday, August 14th. This represents a $6.92 annualized dividend and a yield of 0.6%. Eli Lilly and Company's dividend payout ratio is currently 24.58%.

Analysts Set New Price Targets

LLY has been the topic of several analyst reports. Citigroup raised their price target on shares of Eli Lilly and Company from $1,500.00 to $1,600.00 and gave the company a "buy" rating in a research note on Wednesday, July 15th. Sanford C. Bernstein increased their price objective on Eli Lilly and Company from $1,300.00 to $1,385.00 and gave the stock an "outperform" rating in a report on Tuesday, July 14th. Wall Street Zen cut Eli Lilly and Company from a "strong-buy" rating to a "buy" rating in a research report on Saturday, July 18th. Truist Financial lifted their target price on Eli Lilly and Company from $1,281.00 to $1,370.00 and gave the company a "buy" rating in a research note on Wednesday, July 8th. Finally, Guggenheim increased their price target on Eli Lilly and Company from $1,235.00 to $1,273.00 and gave the stock a "buy" rating in a research note on Monday, July 13th. Two analysts have rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Eli Lilly and Company presently has a consensus rating of "Moderate Buy" and a consensus price target of $1,283.64.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly’s pipeline beyond its GLP-1 weight-loss franchise—including oncology and other newer medicines—is expected to support future growth and diversify the business. Analysts also point to several potentially important programs moving through development. Lilly pipeline article
• Positive Sentiment: The company’s $2.8 billion acquisition of AtaiBeckley expands its presence in emerging psychedelic-based mental-health treatments, signaling that Lilly is investing beyond its current GLP-1 leadership. Lilly AtaiBeckley acquisition article
• Positive Sentiment: Expansion of research and development activity in China, along with plans for a new Lehigh Valley manufacturing plant, could strengthen Lilly’s global research and production capacity. Lilly China R&D article
• Neutral Sentiment: Lilly is one of the market’s most closely watched companies in next week’s earnings slate. The report may be a near-term catalyst, particularly as investors assess demand for its GLP-1 medicines and progress in its broader portfolio. Week ahead earnings preview
• Negative Sentiment: Pre-earnings estimates are mixed. Zacks says Lilly may lack the indicators typically associated with an earnings beat, while Erste Group reduced its FY2026 EPS forecast to $35.34 from $36.33. That caution may be weighing on the stock ahead of results. Lilly earnings expectations

Eli Lilly and Company Company Profile

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.